High-throughput oncogene mutation profiling in human cancer

Nature Genetics

Volumn 39, Issue 3, 2007, Pages 347-351

  Thomas, Roman K ^a,b,p   Baker, Alissa C ^a   DeBiasi, Ralph M ^a,b   Winckler, Wendy ^a,b   LaFramboise, Thomas ^a,b   Lin, William M ^a,b   Wang, Meng ^a,b   Feng, Whei ^a,b   Zander, Thomas ^p   MacConnaill, Laura E ^a,b   Lee, Jeffrey C ^a,b   Nicoletti, Rick ^a,b   Hatton, Charlie ^a,b   Goyette, Mary ^b   Girard, Luc ^c   Majmudar, Kuntal ^c   Ziaugra, Liuda ^b   Wong, Kwok Kin ^a   Gabriel, Stacey ^b   Beroukhim, Rameen ^a,b   Peyton, Michael ^c   Barretina, Jordi ^a,b   Dutt, Amit ^a,b   Emery, Caroline ^a   Greulich, Heidi ^a,b   Shah, Kinjal ^a,b   Sasaki, Hidefumi ^d   Gazdar, Adi ^c,e   Minna, John ^c   Armstrong, Scott A ^a   Mellinghoff, Ingo K ^f   Hodi, F Stephen ^a   Dranoff, Glenn ^a   Mischel, Paul S ^f   Cloughesy, Tim F ^f   Nelson, Stan F ^f   Liau, Linda M ^f   Mertz, Kirsten ^g,h   Rubin, Mark A ^g   Moch, Holger ^h   Loda, Massimo ^a,g   Catalona, William ⁱ   Fletcher, Jonathan ^a,g   Signoretti, Sabina ^a,g   Kaye, Frederic ^j   Anderson, Kenneth C ^a   Demetri, George D ^a,k   Dummer, Reinhard ^l   Wagner, Stephan ^m   Herlyn, Meenhard ⁿ   Sellers, William R ^a,o   Meyerson, Matthew ^a,b   Garraway, Levi A ^a,b   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

^d NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ NORTHWESTERN UNIVERSITY   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m Universitatsklinik fur Dermatologie   (Austria)

ⁿ WISTAR INSTITUTE   (United States)

^o NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^p UNIVERSITY OF COLOGNE   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; K RAS PROTEIN; N RAS PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN H RAS; PROTEIN RET; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER GENETICS; COLORECTAL CANCER; CONTROLLED STUDY; DNA DETERMINATION; ENDOMETRIUM CANCER; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENOME ANALYSIS; GENOTYPE; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; LEUKEMIA; LUNG CANCER; LYMPHOMA; MEDULLOBLASTOMA; MELANOMA; MESOTHELIOMA; MULTIPLE MYELOMA; ONCOGENE; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE NEU; ONCOGENE RET; OVARY CANCER; PANCREAS CANCER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSTATE CANCER; SARCOMA;

DNA MUTATIONAL ANALYSIS; GENE EXPRESSION PROFILING; GENOME, HUMAN; GENOTYPE; HUMANS; MUTATION; NEOPLASMS; ONCOGENES;

EID: 33847293670     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng1975     Document Type: Article

References (27)

1. National Human Genome Research Institute. Cancer Sequencing. 〈http://www.genome.gov/cancersequencing/〉 (2006).
2. Sjoblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274 (2006).
3. National Cancer Institute and National Human Genome Research Institute. The Cancer Genome Atlas. /http://cancergenome.nih.gov/index.aspS (2006).
4. Heinrich, M.C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 21, 4342-4349 (2003).
5. Thomas, R.K. et al. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb. Symp. Quant. Biol. 70, 73-81 (2005).
6. Paez, J.G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
7. Pao, W. et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004).
8. Lynch, T.J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
9. Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
10. Thomas, R.K. et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat. Med. 12, 852-855 (2006).
11. Bansal, A. et al. Association testing by DNA pooling: an effective initial screen. Proc. Natl. Acad. Sci. USA 99, 16871-16874 (2002).
12. Werner, M. et al. Large-scale determination of SNP allele frequencies in DNA pools using MALDI-TOF mass spectrometry. Hum. Mutat. 20, 57-64 (2002).
13. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005).
14. Levine, R.L. et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397 (2005).
15. James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (2005).
16. Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005).
17. Chesi, M. et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat. Genet. 16, 260-264 (1997).
18. Nakahara, M. et al. A novel gain-of-function mutation of c-kit gene in gastrointestinal stromal tumors. Gastroenterology 115, 1090-1095 (1998).
19. Heinrich, M.C. et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol. 24, 4764-4774 (2006).
20. Ikediobi, O.N. et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5, 2606-2612 (2006).
21. Lee, J.C. et al. EGFR activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 3, e485 (2006).
22. Wan, P.T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
23. Weinstein, I.B. & Joe, A.K. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol. 8, 448-457 (2006).
24. Bamford, S. et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355-358 (2004).
25. Jiang, J. et al. Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood (2004).
26. Naoki, K., Chen, T.H., Richards, W.G., Sugarbaker, D.J. & Meyerson, M. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 62, 7001-7003 (2002).
27. Paez, J.G. et al. Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplification. Nucleic Acids Res. 32, e71 (2004).